Ivonescimab extended overall survival in PD-L1-positive advanced non-small-cell lung cancer, with interim Phase 3 data from the HARMONi-2 trial showing longer survival than pembrolizumab. In the prespecified analysis, median overall survival reached 30.8 months on ivonescimab versus 22.6 months on pembrolizumab. The result positions the investigational agent as a potential step-change in first-line or early-line PD-L1-directed combination strategy depending on trial design and patient selection. For biotech and pharma, it also signals continued investor and clinical focus on antibody formats and combinations aimed at outpacing current PD-1 pathway benchmarks. Next checkpoints for the program include final overall survival maturity, objective response durability, and safety comparisons against the pembrolizumab backbone as the trial completes follow-up.